| Serial Number | 98432118 |
| Word Mark | MIRADOR360 |
| Filing Date | Monday, March 4, 2024 |
| Status | 686 - PUBLISHED FOR OPPOSITION |
| Status Date | Tuesday, February 25, 2025 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, February 25, 2025 |
| Pseudo Mark | MIRADOR THREE SIXTY |
| Pseudo Mark | MIRADOR THREE SIX ZERO |
| Pseudo Mark | MIRADOR THREE HUNDRED SIXTY |
| Goods and Services | Scientific research services in the nature of collecting and analyzing patient data and genetic information for pharmaceutical drug development and diagnostics development including companion diagnostics development and complementary diagnostics development; Scientific research services in the nature of collecting and analyzing patient data including genetic information for selecting and validating therapeutic targets for pharmaceutical development as well as for predicting, measuring or evaluating the performance of therapeutic molecules directed at therapeutic targets; Scientific research services in the nature of collecting and analyzing patient data including genetic information for selecting and validating biomarkers and other criteria for diagnostics including companion diagnostics development and complementary diagnostics development as well as for predicting, measuring or evaluating the performance of the diagnostics; Scientific research services in the nature of collecting and analyzing patient data including genetic information for selecting and validating biomarkers and other criteria for selecting patients for inclusion in clinical treatment including clinical trials as well as for predicting, measuring or evaluating the performance of the patient selecting criteria; Scientific research services in the nature of collecting patient data and genetic information and analysis of such data for identifying and recruiting patients for participation in clinical trials for pharmaceutical drug development, matching patients with clinical trials and for measuring and monitoring the performance of clinical trials for pharmaceutical drug development; providing a platform as a service featuring a computer software platform for selecting, validating and evaluating therapeutic targets and therapeutic molecules in the field of pharmaceutical development; providing a platform as a service featuring a computer software platform for selecting, validating and evaluating biomarkers and other patient-selecting or patient-identifying criteria in the field of diagnostic development including companion diagnostics development and complementary diagnostics development |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Monday, March 4, 2024 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Mirador Therapeutics, Inc. |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | San Diego, CA 92121 |
| Party Name | Mirador Therapeutics, Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | San Diego, CA 92121 |
| Event Date | Event Description |
| Monday, March 4, 2024 | NEW APPLICATION ENTERED |
| Monday, July 15, 2024 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Thursday, October 10, 2024 | NON-FINAL ACTION WRITTEN |
| Thursday, January 9, 2025 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Wednesday, September 18, 2024 | ASSIGNED TO EXAMINER |
| Thursday, October 10, 2024 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Thursday, October 10, 2024 | NON-FINAL ACTION E-MAILED |
| Thursday, January 9, 2025 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Thursday, January 9, 2025 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Monday, February 3, 2025 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Tuesday, February 25, 2025 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Wednesday, February 19, 2025 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, February 25, 2025 | PUBLISHED FOR OPPOSITION |